awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB
Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB
Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.
P2860
Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
87b19f247f0b324531b3e522379464399b767dfc
P2860
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.